Immuneering Corp (IMRX) Form 10-Q — Oct 29, 2026
Immuneering reported a Q3 2026 net loss of $24.2 million ($54.9 million for nine months), with R&D expense jumping 90.7% YoY to $20.7 million, driven by an $8.5 million increase in costs for its MAPKeeper 301 Phase 3 trial of atebimetinib in first-line pancreatic cancer. The company raised its MAPKeeper 301 enrollment target from 510 to approximately 570 patients, saying enrollment is ahead of schedule, while maintaining a mid-2028 topline readout (with potential to accelerate).
Key figures
- Total Assets
- 182561047
- Cash Position
- 58226805
- Shares Outstanding
- 64763155
- Phase2 DCR pct
- 82
- Phase2 ORR pct
- 36
- Q3 rnd expense
- 20721243
- Q3 rnd yoy pct
- 90.7
- Topline readout
- mid-2028
- Phase2 m OS months
- 17.3
- Accumulated deficit
- 335200000
- Atm capacity remaining
- 98700000
- Prior enrollment target
- 510
- Standard of care m OS months
- 8.5
- Mapkeeper301 enrollment target
- 570
- Cash plus marketable securities
- 166100000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.